SYROS PHARMACEUTICALS, INC. 4,939,591 shares of common stock, par value $0.001 per share (the “Common Stock”) Pre-Funded Warrants to Purchase 5,242,588 Shares of Common Stock Underwriting AgreementLetter Agreement • December 19th, 2023 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 4,939,591 shares (the “Shares”) of Common Stock of the Company (the “Common Stock”) and pre-funded warrants to purchase an aggregate of 5,242,588 shares of Common Stock in a form to be mutually agreed upon by the Company and the Representatives (the “Warrants”). The shares of Common Stock issuable upon exercise of the Warrants are referred to herein as the “Warrant Shares.” The Shares and Warrants are herein referred to as the “Securities.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares and the exercise of the Warrants are referred to herein as the “Stock.”
